These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 7410856)

  • 1. The effects of mild reduction on the structure and function of C3.
    Isenman DE; Sundsmo JS; Cooper NR
    J Immunol; 1980 Oct; 125(4):1798-805. PubMed ID: 7410856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active sites in complement components C5 and C3 identified by proximity to indels in the C3/4/5 protein family.
    Low PJ; Ai R; Ogata RT
    J Immunol; 1999 Jun; 162(11):6580-8. PubMed ID: 10352274
    [TBL] [Abstract][Full Text] [Related]  

  • 3. C3 requirements for formation of alternative pathway C5 convertase.
    Daha MR; Fearon DT; Austen KF
    J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of reduction on the structural, biologic, and immunologic properties of the third component of human complement.
    Zemel ES; Cartwright-Harwick CM; Nilsson UR
    J Immunol; 1980 Sep; 125(3):1099-103. PubMed ID: 7410831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A single arginine to tryptophan interchange at beta-chain residue 458 of human complement component C4 accounts for the defect in classical pathway C5 convertase activity of allotype C4A6. Implications for the location of a C5 binding site in C4.
    Ebanks RO; Jaikaran AS; Carroll MC; Anderson MJ; Campbell RD; Isenman DE
    J Immunol; 1992 May; 148(9):2803-11. PubMed ID: 1573269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The functions of the ninth component of human complement are sustained by disulfide bonds with different susceptibilities to reduction.
    Hatanaka M; Seya T; Inai S; Shimizu A
    Biochim Biophys Acta; 1994 Nov; 1209(1):117-22. PubMed ID: 7947973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Active sites in complement component C3 mapped by mutations at indels.
    Ogata RT; Ai R; Low PJ
    J Immunol; 1998 Nov; 161(9):4785-94. PubMed ID: 9794410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Purification of a lamprey complement protein homologous to the third component of the mammalian complement system.
    Nonaka M; Fujii T; Kaidoh T; Natsuume-Sakai S; Nonaka M; Yamaguchi N; Takahashi M
    J Immunol; 1984 Dec; 133(6):3242-9. PubMed ID: 6491286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surface modulation of classical pathway activation: C2 and C3 convertase formation and regulation on sheep, guinea pig, and human erythrocytes.
    Brown EJ; Ramsey J; Hammer CH; Frank MM
    J Immunol; 1983 Jul; 131(1):403-8. PubMed ID: 6602833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
    Weiler JM; Gleich GJ
    J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Robust Method to Store Complement C3 With Superior Ability to Maintain the Native Structure and Function of the Protein.
    Adler A; Manivel VA; Fromell K; Teramura Y; Ekdahl KN; Nilsson B
    Front Immunol; 2022; 13():891994. PubMed ID: 35592325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reaction mechanism of human C5 in immune hemolysis.
    Cooper NR; Müller-Eberhard HJ
    J Exp Med; 1970 Oct; 132(4):775-93. PubMed ID: 5508377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interference of propamidine with binding of the fifth component of complement to surface-fixed C3b, and with C5 activation.
    Vogt W; Schmidt G; Hinsch B
    Immunology; 1979 Jan; 36(1):139-43. PubMed ID: 422225
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the fifth and sixth components of the human complement system: C6-dependent cleavage of C5 in acid and the formation of a bimolecular lytic complex, C5b,6a.
    Hammer CH; Hänsch G; Gresham HD; Shin ML
    J Immunol; 1983 Aug; 131(2):892-8. PubMed ID: 6863934
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The activation of C5 in the fluid phase and in the absence of C3 through the classical pathway of the complement system.
    Kitamura H; Tsuboi M; Nagaki K
    Immunology; 1986 Jul; 58(3):459-65. PubMed ID: 3733147
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
    Sahu A; Kay BK; Lambris JD
    J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular basis of complement resistance of human melanoma cells expressing the C3-cleaving membrane protease p65.
    Ollert MW; Kadlec JV; Petrella EC; Bredehorst R; Vogel CW
    Cancer Res; 1993 Feb; 53(3):592-9. PubMed ID: 8425193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
    Kozlov LV; Shibanova ED; Zinchenko AA
    Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of the C3b binding site in a recombinant vWF-A domain of complement factor B by surface-enhanced laser desorption-ionisation affinity mass spectrometry and homology modelling: implications for the activity of factor B.
    Hinshelwood J; Spencer DI; Edwards YJ; Perkins SJ
    J Mol Biol; 1999 Nov; 294(2):587-99. PubMed ID: 10610782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homozygous human C3 deficiency. The role of C3 in antibody production, C-1s-induced vasopermeability, and cobra venom-induced passive hemolysis.
    Alper CA; Colten HR; Gear JS; Rabson AR; Rosen FS
    J Clin Invest; 1976 Jan; 57(1):222-9. PubMed ID: 1107355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.